Tax
Current State and Local Tax Expense (Benefit)
Vertex Pharmaceuticals Current State and Local Tax Expense (Benefit) remained flat by 0.0% to $8.98M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 69.6%, from $29.55M to $8.98M. Over 2 years (FY 2023 to FY 2025), Current State and Local Tax Expense (Benefit) shows a downward trend with a -11.8% CAGR.
Analysis
StatementIncome Statement
SectionTax
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
Metric ID:
ms_current_state_and_local_tax_expenseHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $46.20M | $118.20M | $35.90M |
| YoY Change | — | +155.8% | -69.6% |
Range$35.90M – $118.20M
CAGR-11.8%
Avg YoY Growth+43.1%
Median YoY Growth+43.1%
Current State and Local Tax Expense (Benefit) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's current state and local tax expense (benefit)?
- Vertex Pharmaceuticals (VRTX) reported current state and local tax expense (benefit) of $8.98M in Q4 2025.
- How has Vertex Pharmaceuticals's current state and local tax expense (benefit) changed year-over-year?
- Vertex Pharmaceuticals's current state and local tax expense (benefit) decreased by 69.6% year-over-year, from $29.55M to $8.98M.
- What is the long-term trend for Vertex Pharmaceuticals's current state and local tax expense (benefit)?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's current state and local tax expense (benefit) has grown at a -11.8% compound annual growth rate (CAGR), from $46.20M to $35.90M.